Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 1.35% 7.50 7.00 8.00 7.50 7.125 7.40 581,478 14:56:42
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.3 -0.6 -0.5 - 12

IQ-AI Limited IQAI Awarded "Gad-Free" Patent

11/06/2021 7:00am

UK Regulatory (RNS & others)

Iq-ai (LSE:IQAI)
Historical Stock Chart

From May 2021 to Jul 2021

Click Here for more Iq-ai Charts.


RNS Number : 5624B

IQ-AI Limited

11 June 2021

11 June 2021


("IQ-AI" or the "Company")

IQAI Awarded "Gad-Free" Patent For Medical Imaging Procedures

IQ-AI Limited (LON: IQAI), and its subsidiary, Imaging Biometrics, LLC (IB) announced today that its synthetic T1+C ("Gad-Free") software application was awarded a patent by the U.S. Patent and Trademark Office. This ground-breaking technology eliminates the need to intravenously inject contrast agent during medical imaging procedures. The patent underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.

The fully automated AI platform accepts commonly acquired non-contrast medical images as inputs, and outputs a synthetic contrast enhanced image series that mimic actual, with contrast, images. The 0% contrast dose approach offers remarkable benefits which include a more comfortable patient experience, and the alleviation of potential problems arising from the long-term effects of repeated Gadolinium-based contrast agent (GBCA) use. While the long-term side effects of GBCAs remain unclear, a non-contrast alternative negates the safety implications for patients as well as potential liability concerns for healthcare providers.

"This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally," said Trevor Brown, CEO of IQAI.

The Directors of the Company accept responsibility for the contents of this announcement.


For further information, please contact:

 IQ-AI Limited 
  Trevor Brown/Vinod Kaushal/Qu Li 
  Tel: 020 7469 0930 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Mark Anwyl 
  Tel: 020 7220 9797 

ABOUT Imaging Biometrics , LLC

Imaging Biometrics(R), a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

June 11, 2021 02:00 ET (06:00 GMT)

1 Year Iq-ai Chart

1 Year Iq-ai Chart

1 Month Iq-ai Chart

1 Month Iq-ai Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 07:37:44